Stock: Eli Lilly Surpasses Novo Nordisk in Weight Loss Drug Sales, Shares Soar

[Para 1: The Lead] Eli Lilly (LLY) outperforms Novo Nordisk (NVO) in weight loss drug sales, with LLY's stock climbing double digits. Eli Lilly forecasted a 43% sales surge in its Q4, bolstered by Mounjaro and Zepbound, while Novo Nordisk's shares drop 17% amid forecasted sales declines in 2026. [Para 2-3: Supporting details & Context] Eli Lilly's earnings per share rose 51%, and net income increased 50%. Global revenues for Mounjaro climbed 110% to $7.4 billion, with U.S. sales topping $4 billion, up 59.5%. Outside the U.S., revenues reached $3.3 billion, a 266.7% increase from $900 million. Zepbound sales also saw a 122% jump to over $4 billion. In contrast, Novo Nordisk, despite FDA approval of Wegovy, projects declining sales and profit in 2026 due to U.S. health policy changes and patent expirations in some markets. Eli Lilly's strong market position and financials highlight its competitive edge in the weight loss drug sector.